{"id":"pegfilgrastim-cbqv","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201568","moleculeType":"Protein"},"_dailymed":{"setId":"a8c290ee-b699-4395-a596-1453d4a4b4eb","title":"UDENYCA (PEGFILGRASTIM-CBQV) INJECTION, SOLUTION [COHERUS ONCOLOGY, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their maturation and release into the bloodstream. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. It is used to prevent chemotherapy-induced neutropenia and reduce the risk of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy.","oneSentence":"Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:01:33.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"},{"name":"Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT00304070","phase":"PHASE3","title":"Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-05-03","conditions":"Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7","enrollment":78},{"nctId":"NCT04971304","phase":"","title":"Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars","status":"COMPLETED","sponsor":"Catherine M. Lockhart","startDate":"2015-03-01","conditions":"Cancer, Breast, Cancer, Lung, Cancer of Colon","enrollment":16506},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT04662892","phase":"","title":"An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca","status":"UNKNOWN","sponsor":"Coherus Oncology, Inc.","startDate":"2020-08-01","conditions":"Febrile Neutropenia, Non-myeloid Malignancy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"EMBOLISM"},{"count":2,"reaction":"FEBRILE NEUTROPENIA"},{"count":2,"reaction":"MALAISE"},{"count":2,"reaction":"NEUTROPENIA"},{"count":2,"reaction":"PNEUMONITIS"},{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":1,"reaction":"APPLICATION SITE ERYTHEMA"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neulasta","pegfilgrastim biosimilar"],"phase":"marketed","status":"active","brandName":"Pegfilgrastim-Cbqv","genericName":"Pegfilgrastim-Cbqv","companyName":"Coherus Oncology, Inc.","companyId":"coherus-oncology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-02T00:00:00.000Z","mah":"COHERUS BIOSCIENCES INC","brand_name_local":"UDENYCA","application_number":"BLA761039"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}